GO 203 2c

Drug Profile

GO 203 2c

Alternative Names: GO2032c

Latest Information Update: 21 Dec 2016

Price : $50

At a glance

  • Originator Genus Oncology
  • Developer Dana-Farber Cancer Institute; Genus Oncology
  • Class Antineoplastics; Peptides
  • Mechanism of Action Mucin 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Acute lymphoblastic leukaemia
  • No development reported Solid tumours

Most Recent Events

  • 09 Dec 2016 Dana-Farber Cancer Institute withdrew a phase I trial prior to enrolment in Multiple myeloma (Second-line therapy or greater, Combination therapy) in USA (NCT02658396)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
  • 13 Jan 2016 Dana-Farber Cancer Institute plans a phase I trial for Multiple myeloma (Second-line therapy or greater, Combination therapy) in USA (NCT02658396)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top